Clovis Oncology Plummets After Rociletinib Approval Rejected By: Benzinga via Benzinga April 12, 2016 at 16:25 PM EDT Shares of Clovis Oncology Inc (NASDAQ: CLVS) fell more than 5 percent on Tuesday. The company announced the U.S. Food and Drug ... Read More >> Related Stocks: Clovis Oncology Inc